Group 1: Procurement Policy and Market Dynamics - The focus of the procurement policy has shifted from "expanding coverage and reducing prices" to "stabilizing prices and improving quality" as stated in the 2023 Government Work Report [2] - The blood dialysis consumables alliance has expanded to cover 23 provinces by 2024, indicating a nationwide implementation of procurement [2] - The company has successfully bid for all major products within the procurement scope, ensuring a competitive pricing advantage [2][3] Group 2: International Business Development - In 2024, the company's overseas business generated revenue of 27,412.03 million yuan, a year-on-year increase of approximately 40%, with blood purification product revenue growing by about 67% [4] - The company has registered blood purification products in Indonesia, Peru, and Mexico, and is accelerating certification processes in Russia and Turkey [4] - Future plans include expanding the self-certification scope in emerging markets such as Southeast Asia, South America, and Africa [4] Group 3: Market Share and Product Development - The company holds a leading market share in dialysis concentrate (powder) products, with production bases established in Jiangxi, Yunnan, Sichuan, and Heilongjiang [5] - A new production line for dialysis concentrate with a capacity of 30 million patient doses is being developed in Jiangxi, further solidifying the company's industry position [5] - The market for blood dialysis equipment has significant potential for domestic replacement, with the company's sales increasing by over 100% year-on-year in 2024 [6] Group 4: Future Outlook and Strategic Initiatives - The company is focused on innovating and upgrading blood dialysis products and expanding into various renal management areas, including diabetes and early-stage kidney disease [7][8] - The company aims to enhance its product offerings and commercialize new products to improve operational performance [8] - The procurement policy's emphasis on quality will create higher demands for product supply capabilities, benefiting leading enterprises in the industry [8]

三鑫医疗分析师会议 调研日期：2025年04月21日 调研行业：医疗器械 参与调研的机构：华商基金等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL CARD | | | 颜的集团 ...

Group 1: Financial Performance - In 2024, the company achieved a revenue of 150,043.84 million yuan, representing a year-on-year growth of 15.41% [2] - Overseas business generated a revenue of 27,412.03 million yuan, with a year-on-year increase of 39.70% [2] - Blood dialysis equipment sales volume increased by 120% year-on-year due to successful product registrations in countries like Indonesia, Peru, and Mexico [6] Group 2: Market Expansion Strategy - The company plans to expand its overseas self-certification scope, focusing on emerging markets in Southeast Asia, South America, and Africa [3][4] - The company aims to enhance its international market layout by building a global self-certification system for blood purification products [3] - Future product line expansions will include CRRT and blood dialysis filtration products to solidify the company's industry position [4] Group 3: Competitive Advantages - The company holds a high market share in blood dialysis solutions, supported by four major production bases that enhance service responsiveness and reduce transportation costs [7] - The introduction of personalized dialysis products, such as low-calcium dialysis concentrates, meets specific patient needs and strengthens competitive positioning [7] - The domestic production of medical-grade polyethersulfone (PES) materials is expected to enhance the competitiveness of dialysis membranes and devices [8] Group 4: Response to Market Challenges - The company has developed strategies to address price pressures from centralized procurement policies, including flexible pricing systems and cost reduction measures [5] - The impact of raw material price fluctuations on production costs is significant, and the company has implemented procurement strategies to mitigate these effects [5] - The company is committed to maintaining a robust quality management system to ensure product safety and effectiveness [5] Group 5: Future Product Development - The company is advancing the development of a needle-free injector to improve patient comfort and medication absorption efficiency [11] - The PTA high-pressure balloon dilation catheter has been registered and is expected to accelerate the domestic replacement of imported products [13] - The company plans to continue innovating and optimizing the production of its dialysis-related products to meet clinical needs and enhance patient experience [10]